Since its introduction in 2017, the Beacon® platform has transformed how cell line development (CLD) teams reduce campaign risk and accelerate timelines. Today, over a third of CLD teams worldwide use the Beacon platform to streamline workflows and improve decision-making earlier in the process [1]. One of the greatest challenges in CLD is identifying clones […]
Explore Cell Line Development Articles
This past February and March, Bruker Cellular Analysis, in partnership with BioProcess International, hosted a dynamic two-part webinar series – Pushing the Boundaries in Cell Line Development – spotlighting the capabilities of the Beacon® Optofluidic platform for cell line development (CLD). Now available on demand, these sessions offer a front-row view into how cutting-edge technology […]
In the complex world of biologics manufacturing, cell line development (CLD) plays a crucial role in bringing new biologic therapies to patients.
Bispecific Antibodies: An Emerging Therapeutic Paradigm Bispecific antibodies (bsAbs) are rapidly gaining momentum in the pharmaceutical industry as a revolutionary class of therapeutics. While monoclonal antibodies (mAbs) have dominated the biologics landscape for decades, bsAbs offer unique therapeutic mechanisms by targeting two different antigens simultaneously. This capability enables novel treatment strategies, particularly in cancer immunotherapy, […]
In the biopharmaceutical industry, where lengthy antibody therapeutic development timelines can delay critical treatments for patients in need, accelerating cell line development (CLD) has never been more crucial. The Beacon® optofluidic system by Bruker Cellular Analysis has emerged as a revolutionary platform, offering unparalleled efficiency in CLD processes by enabling a suite of powerful assays […]

